Blocking GDF8 and activin A prevents muscle loss caused by GLP-1 and boosts fat loss in obese male mice and primates

Dual blockade of GDF8 and activin A may prevent muscle loss and could increase muscle mass when using glucagon-like peptide-1 receptor agonists.

• Glucagon-like peptide-1 receptor agonists are linked to significant muscle loss due to mechanisms that conserve energy during periods of reduced caloric intake.
• Activation of type II activin receptors is associated with a reduction in muscle mass.
• Blocking GDF8 and activin A, which are key ligands of activin receptors, may counteract muscle loss.
• In studies with obese mice and non-human primates, dual blockade resulted in muscle preservation and an increase in muscle mass.
• Muscle preservation was also correlated with enhanced fat loss and metabolic benefits.

Simplified